FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2744059590> ?p ?o ?g. }

• W2744059590 endingPage "1787" @default.
• W2744059590 startingPage "1778" @default.
• W2744059590 abstract "PurposeTo evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized visual acuity (VA) stabilization criteria in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).DesignPhase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study.ParticipantsA total of 455 patients.MethodsPatients were randomized (2:2:1) to ranibizumab 0.5 mg (n = 183), ranibizumab 0.5 mg with laser (n = 180), or laser (with optional ranibizumab 0.5 mg after month 6; n = 92). After initial 3 monthly injections, patients in the ranibizumab with or without laser arms received VA stabilization criteria-driven PRN treatment. Patients assigned to the laser arm received laser at the investigator's discretion.Main Outcome MeasuresMean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) from baseline to month 24, and safety over 24 months.ResultsA total of 380 patients (83.5%) completed the study. Ranibizumab with or without laser led to superior BCVA outcomes versus laser (monotherapy and combined with ranibizumab from month 6; 17.3/15.5 vs. 11.6 letters; P < 0.0001). Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average BCVA change: 15.4 vs. 15.0 letters; P < 0.0001). However, addition of laser did not reduce the number of ranibizumab injections (mean injections: 11.4 vs. 11.3; P = 0.4259). A greater reduction in CSFT was seen with ranibizumab with or without laser versus laser monotherapy over 24 months from baseline (ranibizumab monotherapy −224.7 μm, ranibizumab with laser −248.9 μm, laser [monotherapy and combined with ranibizumab from month 6] −197.5 μm). Presence of macular ischemia did not affect BCVA outcome or treatment frequency. There were no reports of neovascular glaucoma or iris neovascularization. No new safety signals were identified.ConclusionsThe BRIGHTER study results confirmed the long-term efficacy and safety profile of PRN dosing driven by individualized VA stabilization criteria using ranibizumab 0.5 mg in patients with BRVO. Addition of laser did not lead to better functional outcomes or lower treatment need. The safety results were consistent with the well-established safety profile of ranibizumab. To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized visual acuity (VA) stabilization criteria in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). Phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study. A total of 455 patients. Patients were randomized (2:2:1) to ranibizumab 0.5 mg (n = 183), ranibizumab 0.5 mg with laser (n = 180), or laser (with optional ranibizumab 0.5 mg after month 6; n = 92). After initial 3 monthly injections, patients in the ranibizumab with or without laser arms received VA stabilization criteria-driven PRN treatment. Patients assigned to the laser arm received laser at the investigator's discretion. Mean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) from baseline to month 24, and safety over 24 months. A total of 380 patients (83.5%) completed the study. Ranibizumab with or without laser led to superior BCVA outcomes versus laser (monotherapy and combined with ranibizumab from month 6; 17.3/15.5 vs. 11.6 letters; P < 0.0001). Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average BCVA change: 15.4 vs. 15.0 letters; P < 0.0001). However, addition of laser did not reduce the number of ranibizumab injections (mean injections: 11.4 vs. 11.3; P = 0.4259). A greater reduction in CSFT was seen with ranibizumab with or without laser versus laser monotherapy over 24 months from baseline (ranibizumab monotherapy −224.7 μm, ranibizumab with laser −248.9 μm, laser [monotherapy and combined with ranibizumab from month 6] −197.5 μm). Presence of macular ischemia did not affect BCVA outcome or treatment frequency. There were no reports of neovascular glaucoma or iris neovascularization. No new safety signals were identified. The BRIGHTER study results confirmed the long-term efficacy and safety profile of PRN dosing driven by individualized VA stabilization criteria using ranibizumab 0.5 mg in patients with BRVO. Addition of laser did not lead to better functional outcomes or lower treatment need. The safety results were consistent with the well-established safety profile of ranibizumab." @default.
• W2744059590 created "2017-08-17" @default.
• W2744059590 creator A5010602494 @default.
• W2744059590 creator A5013612641 @default.
• W2744059590 creator A5018135040 @default.
• W2744059590 creator A5023871553 @default.
• W2744059590 creator A5024261082 @default.
• W2744059590 creator A5040932304 @default.
• W2744059590 creator A5078745000 @default.
• W2744059590 creator A5083564913 @default.
• W2744059590 creator A5087779305 @default.
• W2744059590 date "2017-12-01" @default.
• W2744059590 modified "2023-10-16" @default.
• W2744059590 title "Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion" @default.
• W2744059590 cites W1923935917 @default.
• W2744059590 cites W1963896212 @default.
• W2744059590 cites W1973608834 @default.
• W2744059590 cites W1978704499 @default.
• W2744059590 cites W1995129325 @default.
• W2744059590 cites W2006509301 @default.
• W2744059590 cites W2034477424 @default.
• W2744059590 cites W2052204551 @default.
• W2744059590 cites W2129223002 @default.
• W2744059590 cites W2144771657 @default.
• W2744059590 cites W2212038255 @default.
• W2744059590 cites W2285674438 @default.
• W2744059590 cites W2326434608 @default.
• W2744059590 cites W4237391818 @default.
• W2744059590 doi "https://doi.org/10.1016/j.ophtha.2017.06.027" @default.
• W2744059590 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28807635" @default.
• W2744059590 hasPublicationYear "2017" @default.
• W2744059590 type Work @default.
• W2744059590 sameAs 2744059590 @default.
• W2744059590 citedByCount "84" @default.
• W2744059590 countsByYear W27440595902018 @default.
• W2744059590 countsByYear W27440595902019 @default.
• W2744059590 countsByYear W27440595902020 @default.
• W2744059590 countsByYear W27440595902021 @default.
• W2744059590 countsByYear W27440595902022 @default.
• W2744059590 countsByYear W27440595902023 @default.
• W2744059590 crossrefType "journal-article" @default.
• W2744059590 hasAuthorship W2744059590A5010602494 @default.
• W2744059590 hasAuthorship W2744059590A5013612641 @default.
• W2744059590 hasAuthorship W2744059590A5018135040 @default.
• W2744059590 hasAuthorship W2744059590A5023871553 @default.
• W2744059590 hasAuthorship W2744059590A5024261082 @default.
• W2744059590 hasAuthorship W2744059590A5040932304 @default.
• W2744059590 hasAuthorship W2744059590A5078745000 @default.
• W2744059590 hasAuthorship W2744059590A5083564913 @default.
• W2744059590 hasAuthorship W2744059590A5087779305 @default.
• W2744059590 hasBestOaLocation W27440595901 @default.
• W2744059590 hasConcept C118487528 @default.
• W2744059590 hasConcept C141071460 @default.
• W2744059590 hasConcept C168563851 @default.
• W2744059590 hasConcept C2776694085 @default.
• W2744059590 hasConcept C2777802072 @default.
• W2744059590 hasConcept C2778257484 @default.
• W2744059590 hasConcept C2780261187 @default.
• W2744059590 hasConcept C2780347916 @default.
• W2744059590 hasConcept C2780699112 @default.
• W2744059590 hasConcept C2781100027 @default.
• W2744059590 hasConcept C71924100 @default.
• W2744059590 hasConceptScore W2744059590C118487528 @default.
• W2744059590 hasConceptScore W2744059590C141071460 @default.
• W2744059590 hasConceptScore W2744059590C168563851 @default.
• W2744059590 hasConceptScore W2744059590C2776694085 @default.
• W2744059590 hasConceptScore W2744059590C2777802072 @default.
• W2744059590 hasConceptScore W2744059590C2778257484 @default.
• W2744059590 hasConceptScore W2744059590C2780261187 @default.
• W2744059590 hasConceptScore W2744059590C2780347916 @default.
• W2744059590 hasConceptScore W2744059590C2780699112 @default.
• W2744059590 hasConceptScore W2744059590C2781100027 @default.
• W2744059590 hasConceptScore W2744059590C71924100 @default.
• W2744059590 hasIssue "12" @default.
• W2744059590 hasLocation W27440595901 @default.
• W2744059590 hasLocation W27440595902 @default.
• W2744059590 hasLocation W27440595903 @default.
• W2744059590 hasLocation W27440595904 @default.
• W2744059590 hasOpenAccess W2744059590 @default.
• W2744059590 hasPrimaryLocation W27440595901 @default.
• W2744059590 hasRelatedWork W2121621777 @default.
• W2744059590 hasRelatedWork W2128391312 @default.
• W2744059590 hasRelatedWork W2326434608 @default.
• W2744059590 hasRelatedWork W2586424183 @default.
• W2744059590 hasRelatedWork W2806521176 @default.
• W2744059590 hasRelatedWork W2955043754 @default.
• W2744059590 hasRelatedWork W2967159963 @default.
• W2744059590 hasRelatedWork W3031917678 @default.
• W2744059590 hasRelatedWork W3119603059 @default.
• W2744059590 hasRelatedWork W4285289116 @default.
• W2744059590 hasVolume "124" @default.
• W2744059590 isParatext "false" @default.
• W2744059590 isRetracted "false" @default.
• W2744059590 magId "2744059590" @default.
• W2744059590 workType "article" @default.